SARASOTA, FL -- (MARKET WIRE) -- 02/23/2006 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that during a CBS Early Show broadcast, co-anchor Rene Syler described how the Company's ANCESTRYbyDNA™ test assisted her in determining her family's bio-geographical ancestry.

Syler was joined by her mother in an Early Show segment on Wednesday, February 22, for a discussion about their efforts to learn more about the family's past through DNA testing. Although her family's roots stretched back to Africa, Syler said she wanted to know more about her background in order to teach her children that their history does not begin with slavery.

After taking a basic mitochondrial DNA test, Syler learned that her maternal genetic ancestry included Irish, British or Scandinavian blood. These results piqued Syler's curiosity, because her mother had told her that the family had Native American lineage. Syler then turned to DNAPrint's ANCESTRYbyDNA test, which determined that her makeup was 59 percent sub-Saharan African, 25 percent European, 14 percent Native American, and 2 percent East Asian.

Syler described her reaction to the news as "blown away."

With ancestry, appearances can be deceiving. Anne Syler, the anchor's mother, said she only had a vague idea about their ancestry. "In fact, I was accepted as either French, Indian or Italian even, or Spanish," she said. "People have thought of me as all kinds of races."

Additional details from the program can be found on the CBS News website at http://www.cbsnews.com/stories/2006/02/22/earlyshow/printable1336371.shtml .

DNAPrint Genomics offers a variety of tests for people interested in exploring their family heritage, including African Ancestry mtDNA test. In addition to ANCESTRYbyDNA, the Company's EURO-DNA™ test makes it possible for individuals of European descent to discover their hereditary profile in greater detail. ANCESTRY-MITO traces family origin along the maternal line while ANCESTRY-Y for men traces a paternal line. Ancestry kits offered by the Company come with a mouth swab that is sent back to DNAPrint's laboratory, analyzed, and the results, including genealogical history, are returned on a CD-ROM disc. The basic ANCESTRYbyDNA kit retails for $219.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company for additional forensics work. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results. The Company also performs contract genotyping and other DNA services through its Ellipsis Biotherapeutics group in Toronto, Canada.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
CEO and President
941 366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848